Eisai Co., Ltd. has introduced promising findings for its investigational anti-MTBR antibody, etalanetug, which demonstrated a discount in plasma eMTBR-tau243, a key biomarker related to Alzheimer’s illness (AD) tau tangle pathology. The outcomes have been shared on the Alzheimer’s Association International Conference 2026.
Etalanetug targets the microtubule-binding area of tau protein, doubtlessly stopping the development of tau pathology within the mind. Tau tangles are a trademark of Alzheimer’s and are linked to reminiscence loss and cognitive decline. The investigational drug decreased plasma eMTBR-tau243 by 78% at three months and over 90% at 9 months, intently mirroring modifications noticed in cerebrospinal fluid (CSF).
The examine additionally famous will increase in plasma phosphorylated tau species and t-tau ranges after etalanetug administration, attributed to the stabilization of non-CNS tau species in peripheral tissues. Plasma eMTBR-tau243 was largely absent in wholesome adults, suggesting its specificity to disease-related tau pathology.
Etalanetug’s impression on tau pathology within the mind was additional evidenced by reductions in a number of CSF phosphorylated tau species, together with p-tau205, a marker of late-stage tau pathology. This marks the primary report of an anti-tau remedy decreasing CSF p-tau205 in sufferers with dominantly inherited Alzheimer’s illness (DIAD).
The growth of plasma eMTBR-tau243 as a much less invasive biomarker might play a major position in future scientific developments. Etalanetug is at the moment being evaluated in ongoing scientific research, together with the Tau NexGen Phase II/III trial in DIAD and a Phase II international trial in early sporadic AD, each together with lecanemab.
In September 2025, etalanetug acquired Fast Track designation from the U.S. Food and Drug Administration, underscoring its potential as a disease-modifying remedy for tauopathies.